Suppr超能文献

肺段切除术与肺叶切除术在高代谢临床ⅠA 期肺腺癌中的等效性。

Segmentectomy Is Equivalent to Lobectomy in Hypermetabolic Clinical Stage IA Lung Adenocarcinomas.

机构信息

Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.

Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.

出版信息

Ann Thorac Surg. 2019 Jan;107(1):217-223. doi: 10.1016/j.athoracsur.2018.07.042. Epub 2018 Sep 19.

Abstract

BACKGROUND

Recent studies have suggested that lobectomy and segmentectomy hold equivalent oncologic outcomes, particularly for small, peripheral, subsolid nodules. However, for hypermetabolic nodules that are frequently associated with high rates of nodal disease, recurrence, or mortality, the optimum oncologic procedure was not assessed. We hypothesize that for hypermetabolic, cT1 N0 adenocarcinoma, lobectomy and segmentectomy are associated with comparable outcomes.

METHODS

A prospectively collected database was queried for patients with clinical stage IA lung adenocarcinoma who underwent lobectomy or segmentectomy (2000 to 2016) for hypermetabolic tumors (maximum standard uptake value [SUVmax] ≥ 3g/dL). To obtain balanced groups of patients, a propensity matching analysis was done.

RESULTS

A total of 414 patients had hypermetabolic tumors and underwent lobectomy or segmentectomy. Patients were propensity matched (4:1) (lobectomy: n = 156, segmentectomy: n = 46). Patients in the lobectomy group had a higher rate of pathologic nodal upstaging (17% versus 7%, p = 0.085) and a higher pathologic upstaging rate (38% versus 26%, p = 0.143) than the segmentectomy group. In addition, the lobectomy group had a higher number of resected lymph nodes than the segmentectomy group (median lymph nodes resected: 14 versus 7, p < 0.001). No differences were found in in 5-year recurrence-free survival (RFS; 72% versus 69%, p = 0.679) or in 5-year cancer-specific survival (CSS; 92% versus 83%, p = 0.557) between patients who underwent lobectomy or segmentectomy, respectively.

CONCLUSIONS

Our data show that lobectomy and segmentectomy are comparable oncologic procedures for patients with carefully staged cT1 N0 lung adenocarcinoma with hypermetabolic tumors (SUVmax ≥ 3g/dL). Although lobectomy was associated with a more thorough lymph node dissection, this did not translate into a higher rate of RFS or CSS compared with segmentectomy.

摘要

背景

最近的研究表明,肺叶切除术和肺段切除术的肿瘤学结果相当,尤其是对于小的、外周的、部分实性结节。然而,对于代谢活跃的结节,这些结节通常与较高的淋巴结疾病、复发或死亡率相关,尚未评估最佳的肿瘤学治疗方法。我们假设对于代谢活跃的 cT1N0 肺腺癌,肺叶切除术和肺段切除术具有相似的结果。

方法

通过前瞻性收集数据库,对 2000 年至 2016 年间接受肺叶切除术或肺段切除术(用于代谢活跃的肿瘤[最大标准摄取值(SUVmax)≥3g/dL])治疗的临床 I 期肺腺癌患者进行了检索。为了获得平衡的患者组,进行了倾向匹配分析。

结果

共有 414 例代谢活跃的肿瘤患者接受了肺叶切除术或肺段切除术。对患者进行了倾向匹配(4:1)(肺叶切除术:n=156,肺段切除术:n=46)。肺叶切除术组患者的病理淋巴结分期升高率(17%比 7%,p=0.085)和病理分期升高率(38%比 26%,p=0.143)均高于肺段切除术组。此外,肺叶切除术组的淋巴结清扫数量也多于肺段切除术组(中位数淋巴结清扫数量:14 比 7,p<0.001)。肺叶切除术和肺段切除术患者的 5 年无复发生存率(RFS;72%比 69%,p=0.679)或 5 年癌症特异性生存率(CSS;92%比 83%,p=0.557)均无差异。

结论

我们的数据表明,对于仔细分期的 cT1N0 肺腺癌伴代谢活跃肿瘤(SUVmax≥3g/dL)患者,肺叶切除术和肺段切除术是等效的肿瘤学治疗方法。尽管肺叶切除术与更彻底的淋巴结清扫相关,但与肺段切除术相比,这并未转化为更高的 RFS 或 CSS 率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验